BR112023023391A2 - Inibidor de diminuição de esteroide de receptor de interferon tipo 1 em pacientes com lúpus eritematoso sistêmico - Google Patents
Inibidor de diminuição de esteroide de receptor de interferon tipo 1 em pacientes com lúpus eritematoso sistêmicoInfo
- Publication number
- BR112023023391A2 BR112023023391A2 BR112023023391A BR112023023391A BR112023023391A2 BR 112023023391 A2 BR112023023391 A2 BR 112023023391A2 BR 112023023391 A BR112023023391 A BR 112023023391A BR 112023023391 A BR112023023391 A BR 112023023391A BR 112023023391 A2 BR112023023391 A2 BR 112023023391A2
- Authority
- BR
- Brazil
- Prior art keywords
- lupus erythematosus
- systemic lupus
- patients
- steroid
- receptor type
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163187485P | 2021-05-12 | 2021-05-12 | |
| US202163230113P | 2021-08-06 | 2021-08-06 | |
| PCT/EP2022/062770 WO2022238479A1 (en) | 2021-05-12 | 2022-05-11 | Inhibitor of type 1 interferon receptor steroid sparing in systemic lupus erythematosus patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023023391A2 true BR112023023391A2 (pt) | 2024-01-23 |
Family
ID=82019468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023023391A BR112023023391A2 (pt) | 2021-05-12 | 2022-05-11 | Inibidor de diminuição de esteroide de receptor de interferon tipo 1 em pacientes com lúpus eritematoso sistêmico |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250002591A1 (https=) |
| EP (1) | EP4337696A1 (https=) |
| JP (1) | JP2024516886A (https=) |
| KR (1) | KR20240006549A (https=) |
| AU (1) | AU2022274306A1 (https=) |
| BR (1) | BR112023023391A2 (https=) |
| CA (1) | CA3219401A1 (https=) |
| IL (1) | IL308128A (https=) |
| TW (1) | TW202313103A (https=) |
| WO (1) | WO2022238479A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113278071B (zh) * | 2021-05-27 | 2021-12-21 | 江苏荃信生物医药股份有限公司 | 抗人干扰素α受体1单克隆抗体及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7662381B2 (en) | 2004-06-21 | 2010-02-16 | Medarex, Inc. | Interferon alpha receptor 1 antibodies and their uses |
| KR20160070165A (ko) | 2008-02-08 | 2016-06-17 | 메디뮨 엘엘씨 | Ｆｃ 리간드 친화성이 감소된 항-ＩＦＮＡＲ１ 항체 |
| CA2772921A1 (en) | 2009-09-03 | 2011-03-10 | Medimmune, Llc | Type 1 interferon diagnostic |
| RS64263B1 (sr) * | 2015-08-19 | 2023-07-31 | Astrazeneca Ab | Stabilna anti-ifnar1 formulacija |
| CN106243226B (zh) | 2016-08-05 | 2019-02-12 | 北京智仁美博生物科技有限公司 | 抗人ifnar1的抗体及其用途 |
| CN113278070B (zh) | 2021-04-25 | 2022-06-14 | 福州迈新生物技术开发有限公司 | 抗ck17蛋白单克隆抗体及其细胞株、制备方法和应用 |
-
2022
- 2022-05-11 IL IL308128A patent/IL308128A/en unknown
- 2022-05-11 EP EP22729455.0A patent/EP4337696A1/en active Pending
- 2022-05-11 KR KR1020237038761A patent/KR20240006549A/ko active Pending
- 2022-05-11 JP JP2023568736A patent/JP2024516886A/ja active Pending
- 2022-05-11 CA CA3219401A patent/CA3219401A1/en active Pending
- 2022-05-11 AU AU2022274306A patent/AU2022274306A1/en active Pending
- 2022-05-11 BR BR112023023391A patent/BR112023023391A2/pt unknown
- 2022-05-11 US US18/559,907 patent/US20250002591A1/en active Pending
- 2022-05-11 WO PCT/EP2022/062770 patent/WO2022238479A1/en not_active Ceased
- 2022-05-12 TW TW111117746A patent/TW202313103A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4337696A1 (en) | 2024-03-20 |
| TW202313103A (zh) | 2023-04-01 |
| IL308128A (en) | 2023-12-01 |
| KR20240006549A (ko) | 2024-01-15 |
| AU2022274306A9 (en) | 2023-11-30 |
| AU2022274306A1 (en) | 2023-11-23 |
| JP2024516886A (ja) | 2024-04-17 |
| WO2022238479A1 (en) | 2022-11-17 |
| US20250002591A1 (en) | 2025-01-02 |
| CA3219401A1 (en) | 2022-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017007543A2 (pt) | peptídeos com propriedades anti-inflamatórias | |
| BR112015029987A2 (pt) | beta-caseína a2 e a prevenção de inflamação do intestino | |
| BR112017017217A2 (pt) | ?composição que compreende ramnolipídeo e siloxano? | |
| BR112015027288A8 (pt) | uso de uma dose de imunossupressor, composição de nanocarreadores sintéticos tolerogênicos e kit | |
| BR112022011902A2 (pt) | Terapias de combinação | |
| BR112018009235A8 (pt) | composição de aditivo alimentar | |
| BR112013026392A2 (pt) | arranjo de mancal para uma mola de um chassi de veículo | |
| BR112014012689A8 (pt) | montagem e método de uso de um cateter e método para administração de uma composição antimicrobiana | |
| ECSP088752A (es) | Formulaciones para administración parenteral de compuestos y sus usos | |
| BR0316203A (pt) | Uso de um agente antialérgico e um esteróide para tratar rinite alérgica | |
| BR112018006445A2 (pt) | métodos para tratar distrofia muscular | |
| BR112017009440A2 (pt) | uso de composições que modulam a estrutura de cromatina quanto à doença do enxerto versus hospedeiro (gvhd) | |
| BR112016024022A2 (pt) | composição de silicone curável | |
| BR112017024180A2 (pt) | aparelho de alimentação de rebites | |
| BR112019000989A2 (pt) | método para tratar sulfeto de hidrogênio em uma corrente, sequestrante, composição, e, uso de uma composição | |
| BR112018006368A2 (pt) | composição para desempenho melhorado | |
| BR112023023391A2 (pt) | Inibidor de diminuição de esteroide de receptor de interferon tipo 1 em pacientes com lúpus eritematoso sistêmico | |
| EP4494712A3 (en) | Type i interferon inhibition in systemic lupus erythematosus | |
| BR112014000542A2 (pt) | composições de peroxidase eosinofílica e métodos de uso das mesmas | |
| BR112018067851A2 (pt) | composições e métodos para o tratamento de artrite reumatoide | |
| BR112021024109A2 (pt) | Composições farmacêuticas compreendendo um agonista fxr e um fibrato para uso no tratamento de doença hepática colestática | |
| BR112019000635A2 (pt) | inibidor de receptor 2 do tipo toll (tlr2) e seu uso, anticorpo, composição e método para tratar uma afecção inflamatória | |
| BR112018077147A2 (pt) | processo de tratamento de minério de magnetita, e composição coletora | |
| BR112018006697A2 (pt) | método de controle de alimentação de veículo e dispositivo de controle de alimentação de veículo | |
| BR112013005887A2 (pt) | compostos de sacarídeo substituído e composições dentais |